Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Vaccinex stock

VCNX
US9186401033
A2N30M

Price

3.40
Today +/-
+0.04
Today %
+1.18 %
P

Vaccinex stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Vaccinex stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Vaccinex stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Vaccinex stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Vaccinex's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Vaccinex Stock Price History

DateVaccinex Price
9/30/20243.40 undefined
9/27/20243.36 undefined
9/26/20243.27 undefined
9/25/20243.38 undefined
9/24/20244.23 undefined
9/23/20244.49 undefined
9/20/20244.75 undefined
9/19/20244.55 undefined
9/18/20245.16 undefined
9/17/20246.00 undefined
9/16/20245.73 undefined
9/13/20245.61 undefined
9/12/20245.61 undefined
9/11/20245.67 undefined
9/10/20245.57 undefined
9/9/20245.32 undefined
9/6/20245.63 undefined
9/5/20245.42 undefined
9/4/20245.18 undefined
9/3/20245.49 undefined

Vaccinex Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Vaccinex, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vaccinex from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vaccinex’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vaccinex. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vaccinex’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vaccinex’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vaccinex’s growth potential.

Vaccinex Revenue, EBIT and net profit per share

DateVaccinex RevenueVaccinex EBITVaccinex Net Income
2024e26.74 B undefined0 undefined0 undefined
2023570,000 undefined-22.89 M undefined-20.25 M undefined
2022275,000 undefined-19.91 M undefined-19.82 M undefined
2021900,000 undefined-22.49 M undefined-22.38 M undefined
2020625,000 undefined-28.33 M undefined-28.85 M undefined
2019523,000 undefined-32.02 M undefined-31.86 M undefined
2018724,000 undefined-27.28 M undefined-29.52 M undefined
201790,000 undefined-21.1 M undefined-21.93 M undefined
2016316,000 undefined-20.26 M undefined-26.23 M undefined

Vaccinex Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (k)DOCUMENTS
201620172018201920202021202220232024e
0000000026.74
---------
---------
000000000
-20-21-27-32-28-22-19-220
---------
-26-21-29-31-28-22-19-200
--19.2338.106.90-9.68-21.43-13.645.26-
54.754.654.761.389.5137.4202.1463.70
---------
Details

Keystats

ⓘ

Revenue and Growth

The Vaccinex Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Vaccinex is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (k)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
1.664.1819.722.7810.68.596.391.54
1041176398981570175961
00000000
00000000
0.350.681.060.340.530.820.910.85
2.114.9721.424.0111.299.417.483.35
730601604594416438499282
00000000
00000000
00000000
00000000
00000000
730601604594416438499282
2.845.5822.034.611.79.847.983.63
               
111.42119.400000.010
53.7954.12208.16222.4250.91307.28324.88337.63
-168.53-187.25-216.77-248.63-277.48-299.86-319.68-339.93
00000000
00000000
-3.32-13.72-8.61-26.23-26.567.425.2-2.3
2.461.912.323.213.171.061.522.04
1.981.964.363.671.941.120.951.39
00.3000002.41
00008.07000
00000747475
4.444.176.696.8813.182.262.545.92
1.042.81001.130.180.10.03
00000000
69436900001460
1.733.18001.130.180.250.03
6.177.356.696.8814.312.432.785.94
2.85-6.38-1.92-19.35-12.259.857.993.64
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Vaccinex provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Vaccinex's financial health and stability.

Assets

Vaccinex's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Vaccinex must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Vaccinex after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Vaccinex's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
-13-18-29-31-28-22-19
0000000
0000000
1,00001,0000-1,000-3,0000
-7-220000
0000000
0000000
-19-21-25-30-28-25-19
0000000
00-1414000
00-1414000
0000000
53-509-80
108370283217
16234013362316
012913000
0000000
-421-27-2-2
-20.51-21.46-25.52-30.8-28.94-25.33-19.17
0000000

Vaccinex stock margins

The Vaccinex margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vaccinex. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vaccinex.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vaccinex's sales revenue. A higher gross margin percentage indicates that the Vaccinex retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vaccinex's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vaccinex's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vaccinex's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vaccinex. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vaccinex's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vaccinex Margin History

Vaccinex Gross marginVaccinex Profit marginVaccinex EBIT marginVaccinex Profit margin
2024e100 %0 %0 %
2023100 %-4,014.91 %-3,552.81 %
2022100 %-7,238.55 %-7,205.45 %
2021100 %-2,498.89 %-2,486.67 %
202099.68 %-4,532.96 %-4,616.16 %
201961.95 %-6,121.42 %-6,092.35 %
2018-42.68 %-3,768.09 %-4,077.07 %
2017-77.78 %-23,448.89 %-24,370 %
201663.61 %-6,411.08 %-8,301.58 %

Vaccinex Stock Sales Revenue, EBIT, Earnings per Share

The Vaccinex earnings per share therefore indicates how much revenue Vaccinex has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vaccinex earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vaccinex's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vaccinex’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vaccinex's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vaccinex Revenue, EBIT and net profit per share

DateVaccinex Sales per ShareVaccinex EBIT per shareVaccinex Earnings per Share
2024e5,799.77 undefined0 undefined0 undefined
20231.23 undefined-49.35 undefined-43.67 undefined
20221.36 undefined-98.5 undefined-98.05 undefined
20216.55 undefined-163.68 undefined-162.88 undefined
20206.98 undefined-316.55 undefined-322.36 undefined
20198.53 undefined-522.27 undefined-519.79 undefined
201813.24 undefined-498.74 undefined-539.63 undefined
20171.65 undefined-386.52 undefined-401.7 undefined
20165.78 undefined-370.37 undefined-479.58 undefined

Vaccinex business model

Vaccinex Inc is a biopharmaceutical company based in Rochester, New York, focusing on the development of novel therapies for a variety of diseases. The company was founded in 2001 by Maurice Zylofo and Dr. Steffen Nock, and has since built an impressive track record in drug development. Vaccinex's business model is based on the discovery and development of specific monoclonal antibodies for the treatment of diseases, particularly cancer. The company has developed a proprietary platform technology called ActivMAb®, which quickly and efficiently identifies potential targets and develops specific antibodies to block or modulate these targets. Vaccinex has several business divisions, including cancer therapy, immunology, cardiology, and neurology. Each of these divisions focuses on specific diseases and potential applications of Vaccinex's technology. The company also has partnerships with other industry leaders, such as Bristol-Myers Squibb and Catalent, to support the development and manufacturing of new drugs. The company has conducted several clinical trials to evaluate the efficacy and safety of its products. Vaccinex's most promising products are VX15/2503, a monoclonal antibody targeting cancer, and PEPCON, a potential vaccine for Alzheimer's disease. VX15/2503 is an antibody that targets the semaphorin 4-D receptor, a molecule that plays a key role in cancer development. The drug has shown in preclinical studies that it can inhibit tumor growth and has shown promise in clinical trials for the treatment of lung cancer and an aggressive brain tumor called glioblastoma. PEPCON is a novel vaccine targeting Alzheimer's disease. The vaccine aims to eliminate the beta-amyloid peptide, which is deposited in the brains of patients with Alzheimer's disease. The drug has shown in early clinical studies that it is able to reduce these brain deposits, which may lead to improved cognitive function. Overall, Vaccinex Inc has a promising future and is well-positioned to develop new and innovative therapies for the treatment of diseases. The company has an impressive track record in drug development and partnering with other industry leaders to support the manufacturing and commercialization of new drugs. With a strong pipeline of promising drug candidates, Vaccinex Inc will continue to play an important role in the development of new treatments. Vaccinex is one of the most popular companies on Eulerpool.com.

Vaccinex SWOT Analysis

Strengths

Vaccinex Inc has several strengths that contribute to its competitive advantage. One of the key strengths is its strong intellectual property portfolio, which includes a number of patents and proprietary technologies. This enables the company to protect its innovations and maintain exclusivity in the market. Additionally, Vaccinex Inc benefits from a highly skilled and experienced research and development team, allowing for efficient product development and innovation.

Weaknesses

Despite its strengths, Vaccinex Inc also faces certain weaknesses that may hinder its growth and success. One notable weakness is its limited financial resources. As a relatively small biotechnology company, Vaccinex Inc may face challenges in securing sufficient funding for research and development projects and expanding its operations. Furthermore, the company heavily relies on a small number of products, which increases its vulnerability to market fluctuations and regulatory changes.

Opportunities

Vaccinex Inc operates in a dynamic and rapidly evolving industry, presenting various opportunities for growth and expansion. The increasing demand for innovative therapies and treatments, particularly in the field of immunotherapy, offers a significant market opportunity for the company. Furthermore, Vaccinex Inc can explore strategic partnerships and collaborations with larger pharmaceutical companies to strengthen its product pipeline and access additional resources and expertise.

Threats

Along with opportunities, Vaccinex Inc also faces certain threats that could potentially impact its business operations. The competitive landscape in the biotechnology industry is intense, with numerous well-established players competing for market share. This poses a challenge for Vaccinex Inc to differentiate itself and effectively promote its products. Additionally, regulatory uncertainties and stringent approval processes for new therapies pose a threat to the company's ability to bring new products to market in a timely manner.

Vaccinex Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Vaccinex historical P/E ratio, EBIT multiple, and P/S ratio

Vaccinex shares outstanding

The number of shares was Vaccinex in 2023 — This indicates how many shares 463,700 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vaccinex earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vaccinex's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vaccinex’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vaccinex's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vaccinex stock splits

In Vaccinex's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Vaccinex.

Vaccinex latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20230 -1.09  (0 %)2023 Q3
6/30/20230 -0.12  (0 %)2023 Q2
3/31/20230 -0.1  (0 %)2023 Q1
6/30/2021-0.3 -0.21  (29.01 %)2021 Q2
12/31/2020-0.38 -0.29  (24.71 %)2020 Q4
9/30/2020-0.44 -0.44  (0.83 %)2020 Q3
6/30/2020-0.52 -0.39  (25.03 %)2020 Q2
3/31/2020-0.77 -0.45  (41.18 %)2020 Q1
12/31/2019-0.59 -0.38  (35.77 %)2019 Q4
9/30/2019-0.67 -0.56  (16.82 %)2019 Q3
1
2

Vaccinex shareholders

%
Name
Stocks
Change
Date
2.52811 % Point72 Asset Management, L.P.116,546116,5462/8/2024
2.15896 % Vaccinex (Rochester), L.L.C.99,528-15,9262/8/2024
10.28757 % Friedberg Mercantile Group Ltd.474,257118,2262/8/2024
1.01345 % Worth Venture Partners, LLC46,720-4,53412/31/2023
0.25254 % AIGH Capital Management, LLC.11,642-14,97312/31/2023
0.07824 % Zauderer (Maurice)3,60723/22/2024
0.07471 % The Vanguard Group, Inc.3,444012/31/2023
0.04974 % Renaissance Technologies LLC2,2932,29312/31/2023
0.04933 % Friedberg (Albert D)2,2741813/22/2024
0.04297 % Telemetry Investments, L.L.C.1,981-35212/31/2022
1
2
3
4
5
...
6

Vaccinex Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Merck Stock
Merck
SupplierCustomer0,280,680,530,02-0,22-0,63
Surface Oncology Rg Stock
Surface Oncology Rg
SupplierCustomer-0,130,710,450,100,770,24
Merck & Co Stock
Merck & Co
SupplierCustomer-0,36-0,58-0,35-0,31-0,40-0,24
Biocon Stock
Biocon
SupplierCustomer-0,370,88-0,060,360,500,34
Catalent Stock
Catalent
SupplierCustomer-0,44-0,220,410,010,46-0,39
1

Most common questions regarding Vaccinex

What values and corporate philosophy does Vaccinex represent?

Vaccinex Inc represents values of innovation, dedication, and patient-centricity. With a strong corporate philosophy focused on advancing novel therapies, Vaccinex is committed to transforming the treatment landscape for diseases with high unmet medical needs. The company prioritizes the development of its proprietary pipeline, leveraging its unique ActivmAb® antibody discovery platform. Vaccinex aims to bring forth groundbreaking solutions that address diseases such as cancer and neurodegenerative disorders. By combining cutting-edge technology, scientific expertise, and a patient-centered approach, Vaccinex Inc aims to improve outcomes and make a significant impact in the lives of patients worldwide.

In which countries and regions is Vaccinex primarily present?

Vaccinex Inc is primarily present in the United States.

What significant milestones has the company Vaccinex achieved?

Vaccinex Inc has achieved several significant milestones in its history. Notably, the company successfully completed a Phase 2 clinical trial for its lead product candidate, pepinemab, in patients with Huntington's disease, demonstrating positive efficacy and safety outcomes. Additionally, Vaccinex Inc has secured strategic partnerships and collaborations with renowned pharmaceutical companies, enhancing its research and development capabilities. The company has also been granted various patents for its innovative antibody discovery platform, ActivMab®, further solidifying its intellectual property portfolio. These achievements highlight Vaccinex Inc's commitment to advancing novel therapeutic solutions and its potential for future growth and success.

What is the history and background of the company Vaccinex?

Vaccinex Inc is a pharmaceutical company based in Rochester, New York. Established in 2001, it specializes in the development of targeted biotherapeutics to treat cancer and neurodegenerative diseases. Vaccinex's proprietary technology, known as ActivMAb, allows for the discovery and optimization of monoclonal antibody drugs. Over the years, the company has successfully advanced multiple clinical-stage programs, including its lead candidate, pepinemab, for the treatment of Huntington's disease and non-small cell lung cancer. Vaccinex continues to forge strategic partnerships and collaborations to accelerate the development and commercialization of its innovative therapies.

Who are the main competitors of Vaccinex in the market?

The main competitors of Vaccinex Inc in the market include other biotechnology companies specializing in the development of innovative therapies. With its focus on discovering and developing antibody-based therapies, Vaccinex faces competition from companies such as Genmab, Incyte Corporation, and Regeneron Pharmaceuticals. These competitors also leverage cutting-edge technologies to produce novel therapeutics for various diseases and conditions. Vaccinex Inc differentiates itself through its unique antibody discovery platform, which enables the identification of potential drug candidates with high precision and specificity. Its strong pipeline and strategic collaborations position the company well among its rivals in the biotechnology sector.

In which industries is Vaccinex primarily active?

Vaccinex Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Vaccinex?

The business model of Vaccinex Inc revolves around the development and commercialization of novel antibody-based therapeutics. The company leverages its proprietary ActivMAb platform to discover and optimize antibodies that target specific diseases, including cancer and neurodegenerative disorders. Vaccinex Inc collaborates with partners in the biopharmaceutical industry and academia to advance its pipeline and bring innovative treatments to patients. By focusing on the development of immunotherapies, Vaccinex Inc aims to address unmet medical needs and improve patient outcomes. With a strong emphasis on research and development, the company strives to create value for shareholders and stakeholders in the healthcare sector.

What is the P/E ratio of Vaccinex 2024?

The Vaccinex P/E ratio is 0.

What is the P/S ratio of Vaccinex 2024?

The Vaccinex P/S ratio is 0.

What is the AlleAktien quality score of Vaccinex?

The AlleAktien quality score for Vaccinex is 4/10.

What is the revenue of Vaccinex 2024?

The expected Vaccinex revenue is 26.74 B USD.

How high is the profit of Vaccinex 2024?

The profit cannot currently be calculated for Vaccinex.

What is the business model of Vaccinex

Vaccinex Inc is a biotechnology company focused on developing innovative treatments for cancer and neurodegenerative diseases. They have two main areas of focus: antibody development and small molecule development. The antibody program aims to develop monoclonal antibodies that specifically bind to target molecules in the body to modulate or block their functions. Vaccinex uses their proprietary technology, the ActivMAb® system, to efficiently and quickly produce and select antibodies. They combine ActivMAb® with bioinformatics tools to develop targeted antibodies for difficult-to-treat diseases. Their first product, HuMax-IL8, has reached phase 2 of clinical trials and is being used as a potential cancer therapy. They also have other projects in the preclinical phase, focusing on the treatment of Parkinson's, Alzheimer's, and other neurodegenerative diseases. The small molecule development focuses on developing drugs containing small molecules that can modulate cellular processes. The focus is on enzymes that play a crucial role in cancer development. Through targeted design and screening of molecules, potential drug candidates are identified and their efficacy and safety are tested in early clinical studies. Vaccinex has already initiated several such projects and collaborates with well-known pharmaceutical companies. Overall, Vaccinex's business model is centered around using their proprietary technologies and expertise in antibody and small molecule research to develop innovative therapeutics. They not only develop their own pipeline products but also enter into partnerships with other pharmaceutical companies and grant licenses. The focus on cancer and neurodegenerative diseases promises significant growth potential, along with a clear medical need. In summary, Vaccinex develops, licenses, and distributes innovative therapeutics in the fields of cancer and neurodegenerative diseases. Their antibody and small molecule research allows for the targeted development of drugs that can modulate or block cellular processes and influence the function of disease proteins. The company collaborates with reputable partners in the pharmaceutical industry and has a proprietary technology that efficiently and quickly leads to the discovery and selection of antibodies and drug candidates. The business model promises high growth potential by focusing on areas with significant medical need.

What is the Vaccinex dividend?

Vaccinex pays a dividend of 0 USD distributed over payouts per year.

How often does Vaccinex pay dividends?

The dividend cannot currently be calculated for Vaccinex or the company does not pay out a dividend.

What is the Vaccinex ISIN?

The ISIN of Vaccinex is US9186401033.

What is the Vaccinex WKN?

The WKN of Vaccinex is A2N30M.

What is the Vaccinex ticker?

The ticker of Vaccinex is VCNX.

How much dividend does Vaccinex pay?

Over the past 12 months, Vaccinex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vaccinex is expected to pay a dividend of 0 USD.

What is the dividend yield of Vaccinex?

The current dividend yield of Vaccinex is .

When does Vaccinex pay dividends?

Vaccinex pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vaccinex?

Vaccinex paid dividends every year for the past 0 years.

What is the dividend of Vaccinex?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vaccinex located?

Vaccinex is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vaccinex kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vaccinex from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Vaccinex pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Vaccinex in the year 2023?

In the year 2023, Vaccinex distributed 0 USD as dividends.

In which currency does Vaccinex pay out the dividend?

The dividends of Vaccinex are distributed in USD.

All fundamentals about Vaccinex

Our stock analysis for Vaccinex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vaccinex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.